Study registration: *
Publication Chemaitelly H, medRxiv, 2021
Dates: 2021-02-01 to 2021-07-21
Funding: Mixed (The Biomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core, and the Genomics Core, all at Weill Cornell Medicine-Qatar, as well as the Ministry of Public Health, Hamad Medical Corporation and the Qatar Genome Programme.)
Conflict of interest: no COI (The authors have declared no competing interest.)

Methods

Study design:Cohort
Description of participants: Immunosuppressed kidney transplant recipients in Qatar.
Inclusion criteria:
  • Kidney transplant recipients
  • no prior PCR-confirmed diagnosis
  • alive at the start of the follow-up time (February 1, 2021)

Exclusion criteria:
  • *

Follow-up duration (months): 5.7
Vaccines:
  • 1 or 2 doses of either BNT162b2 or mRNA-1273
Variant description :
Variant name: Beta
Evidence: Indirect evidence (prevalence of variant in the population: 1 to 85%)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Yes
Data accessibility: Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.
General comment Concerns mainly about the possibility of uncontrolled confounding.